Julie Zissimopoulos

Professor, Economist, USC Schaeffer Center for Health Economics and Policy, Price School of Public Policy.

[Julie Zissimopoulos @zissimop]

I’m moving. Please follow me @zisspolicyusc.bsky.social

[Meng Li 李濛 @drmengli]

Super excited to join the all-star team at @TuftsCEVR and looking forward to connecting and collaborating with friends and colleagues in my new role!

[USC Leonard Davis School of Gerontology @USCLeonardDavis]

.@NIHAging has awarded a five-year grant to fund
@USC's RCMAR, which supports junior scientists exploring health & #economic disparities associated with #dementia. https://t.co/ohCnRaC5au… 📊
@USCAgingCog @SchaefferCenter @geronsociety @zissimop @DrAilshire @MJhealthecon

[USC Aging and Cognition @USCAgingCog]

Caring for persons with dementia can force family members to choose between giving up work or paying for costly care. @zissimop delves into the challenges associated with the rising costs of memory care within our aging population on @NPR.
https://t.co/HAOv3Jt1f1

[USC Aging and Cognition @USCAgingCog]

New study by @sidrahaye and colleagues at @SchaefferCenter finds lower diagnosed dementia rates among Medicare Advantage (MA) beneficiaries compared to traditional Medicare (TM), potentially worsening racial/ethnic disparities in dementia diagnosis. https://t.co/4ysFg16VhV

[Health Affairs @Health_Affairs]

In their paper featured in this month’s issue of @Health_Affairs, Alice J. Chen from @USCPrice + @SchaefferCenter and coauthors compare prices and market-share dominance of the cancer drug trastuzumab (Herceptin) and five biosimilars.

[MedPage Today @medpagetoday]

Should cognitive assessments be a regular feature in #preventive care?

According to @zissimop of @SchaefferCenter, a brief assessment in primary care could lead to "more timely treatments... [and] steps to plan for the future." @MedPageNeuro
https://t.co/JNEMcKcVaU

[USC Schaeffer @USCSchaeffer]

"Trastuzumab is the best example to date of biosimilars fulfilling their promise to reduce biologic drug prices," says @USCPrice Prof Alice Chen. She and @KarenVanNuys published in @Health_Affairs on the cancer drug and its biosimilar entrants. https://t.co/RLPJ4yxo4z

[Liana Apostolova, MD, MSc, FAAN @ApostolovaLiana]

I am incredibly honored! I promise to serve with passion and commitment.

https://t.co/cQj2quP7a5

[Alzheimer's & Dementia Journals @alzdemjournals]

Dr. Whitmer also explores early life contributions to brain health and dementia risk, including metabolic and vascular influences on brain aging.

[USC Schaeffer @USCSchaeffer]

"The solution we recommend is to measure a technology’s value in terms of health improvements to patients and then use this quantity to set a maximum fair price," write @USCMann @USCPrice Prof Darius Lakdawalla and colleagues in @Health_Affairs Forefront. https://t.co/dvkt5PeCCZ

[Meng Li 李濛 @drmengli]

Super excited to join the star-studded team @TuftsCEVR !!

[Population Aging Research Center at Penn @PennPARC]

This morning we heard from Julie Zissimopoulos, Samuel Preston, @OS_Mitchell, and Amanda Kreider at Session 1: The New American Demography: Implications for Population Aging
@pilargonalons @SchaefferCenter @PensionResearch @PennLDI

[USC Schaeffer @USCSchaeffer]

Despite the overwhelming burden of dementia, it frequently goes undetected and undiagnosed in the early stages. Schaeffer and @USCPrice Prof @zissimop and colleagues discuss expanding the use of cognitive assessments in this @alzassociation piece. https://t.co/T5UFU7zHZY

[USC Aging and Cognition @USCAgingCog]

New publication from @zissimop and colleagues discusses the need for sweeping changes from multiple stakeholders to improve detection rates of mild cognitive impairment so that patients and families may benefit from timely interventions.
https://t.co/kQaM6zU7YV

[UsAgainstAlzheimer's @UsAgainstAlz]

Changes must be made to improve detection rates of cognitive impairment and #dementia so that patients and families can benefit from early interventions. Read more here - https://t.co/HwbxF3TtJ2 @RussPaulsen @kellymobrien @Dementiaunwoven @nicolefowler123 @MIAging @zissimop

[USC Schaeffer @USCSchaeffer]

Today, Schaeffer's Karen Van Nuys is testifying at @SenateFinance on her PBM research:
"First, in some circumstances, PBMs raise drug costs...Somehow, involving the PBM and the health plan in the transaction increased drug costs by 21%" among 184 generics

https://t.co/aIN0GKSVJx

[CCADMR @ccadmr]

Dr. Julius Fridrikkson @USCArnoldSchool shared the growing need for more Alzheimer's Disease and Related Dementias (ADRD) research, like what @USCReseach and the SC-ADRD Registry are doing to improve brain health. #2023ADRegConf